These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 9723323)

  • 1. Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over 1 year.
    Cooney GF; Jeevanandam V; Choudhury S; Feutren G; Mueller EA; Eisen HJ
    Transplant Proc; 1998 Aug; 30(5):1892-4. PubMed ID: 9723323
    [No Abstract]   [Full Text] [Related]  

  • 2. Conversion from Sandimmune to Neoral in stable heart transplant recipients.
    Pethig K; Ruhparwar A; Korn A; Christians U; Wahlers T
    Transplant Proc; 1996 Aug; 28(4):2287-9. PubMed ID: 8769228
    [No Abstract]   [Full Text] [Related]  

  • 3. Changing stable heart transplant recipients from Sandimmune to Neoral.
    Dalrymple-Hay M; Meara M; Reynolds L; Backhouse L; Wright D; Holt D; Johnston A; Madden B; Murday A
    Transplant Proc; 1996 Aug; 28(4):2285-6. PubMed ID: 8769227
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical impact of Neoral in thoracic organ transplantation.
    Aziz T; el-Gamel A; Keevil B; Krysiak P; Campbell C; Rahman A; Deiraniya A; Yonan N
    Transplant Proc; 1998 Aug; 30(5):1900-3. PubMed ID: 9723326
    [No Abstract]   [Full Text] [Related]  

  • 5. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation, using a dose-adjusted method.
    First MR; Weiskittel P; Shah M; Peddi VR; Canafax D; Schroeder TJ
    Transplant Proc; 1998 Dec; 30(8):3955-7. PubMed ID: 9865260
    [No Abstract]   [Full Text] [Related]  

  • 6. Cyclosporine neoral pharmacokinetics in kidney and heart transplant patients.
    Schiavelli R; Sgrosso JL; Sabbatiello R; Castro C; Ahualli L; Pattin M; Vazquez MC
    Transplant Proc; 1996 Dec; 28(6):3343-4. PubMed ID: 8962299
    [No Abstract]   [Full Text] [Related]  

  • 7. Conversion from standard cyclosporine to Neoral in lung transplant recipients.
    Kesten S; Scavuzzo M; Laurin L; Tan A; Chaparro C
    Transplant Proc; 1998 Aug; 30(5):1895-7. PubMed ID: 9723324
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine pharmacokinetics in renal allograft recipients with diabetes mellitus with Sandimmune and Sandimmune Neoral.
    Serafinowicz A; Gaciong Z; Baçzkowska T; Durlik M; Lao M
    Transplant Proc; 1996 Dec; 28(6):3140-1. PubMed ID: 8962217
    [No Abstract]   [Full Text] [Related]  

  • 10. A bioavailability study of cyclosporine: comparison of Neoral versus Cysporin in stable heart transplant recipients.
    Leet A; Richardson M; Senior JA; Funston R; Skiba M; Bailey M; Krum H
    J Heart Lung Transplant; 2009 Sep; 28(9):894-8. PubMed ID: 19716041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal metabolism of cyclosporine A in human heart transplant recipients.
    Lehle K; Kirchner G; Sewing KF; Rupprecht L; Merk J; Preuner JG
    Transplant Proc; 1998 Dec; 30(8):4044. PubMed ID: 9865289
    [No Abstract]   [Full Text] [Related]  

  • 12. Conversion from Sandimmune to Neoral in stable renal and pancreas transplant recipients enhances cyclosporine absorption.
    Chapman JR; O'Connell PJ; Bovington KJ; Allen RD
    Transplant Proc; 1996 Aug; 28(4):2293-5. PubMed ID: 8769229
    [No Abstract]   [Full Text] [Related]  

  • 13. Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with Sandimmune-Neoral.
    Serafinowicz A; Gaciong Z; Baçzkowska T; Rell K; Lao M; Wałaszewski J
    Transplant Proc; 1996 Dec; 28(6):3138-9. PubMed ID: 8962216
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
    White M; Pelletier GB; Tan A; Jesina C; Carrier M
    J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sandimmun-to-Neoral conversion in stable pediatric kidney transplant recipients.
    Kelles A; Herman J; Tjandra-Maga TB; Van Damme-Lombaerts R
    Transplant Proc; 1998 Aug; 30(5):1995-6. PubMed ID: 9723366
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term safety and efficacy of Neoral in heart transplantation.
    Yonan NA; Aziz T; el-Gamel A; Campbell CS; Rahman AN; Deiraniya AK
    Transplant Proc; 1998 Aug; 30(5):1906-9. PubMed ID: 9723328
    [No Abstract]   [Full Text] [Related]  

  • 17. Neoral conversion study: shift from Sandimmune classic formulation to Neoral in heart and lung transplant patients.
    Svendsen UG; Larsen KR; Allermand H; Thayssen P; Jensen SB; Pettersson G
    Transplant Proc; 1996 Aug; 28(4):2281. PubMed ID: 8769225
    [No Abstract]   [Full Text] [Related]  

  • 18. Follow-up after conversion to Neoral in stable heart transplant recipients.
    Pethig K; Geiger M; Korn A; Grote M; Christians U; Wahlers T
    Transplant Proc; 1996 Aug; 28(4):2282-4. PubMed ID: 8769226
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of conversion from Sandimmune to Neoral on glomerular filtration rate in stable renal transplant recipients.
    Steinmuller D; Dougherty J; Coutee J; Surek D; Swies G; Lewis R
    Transplant Proc; 1997; 29(1-2):298-9. PubMed ID: 9123005
    [No Abstract]   [Full Text] [Related]  

  • 20. Change of conventional cyclosporine to neoral cyclosporine formulation in long-term liver transplant recipients.
    Diliz HS; Olivera MA; Kershenobich D; Mercado MA; Orozco H
    Transplant Proc; 1996 Dec; 28(6):3348-50. PubMed ID: 8962302
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.